Quantumzyme Corp. (OTC: QTZM), a biotransformation company specializing in enzyme-based solutions for pharmaceutical manufacturing, announced today that it plans to attend the 2026 BIO International Convention, scheduled for June 22–25, 2026, in San Diego, California. The BIO International Convention is a premier global gathering of biotechnology and life sciences companies, academic institutions, and industry participants, covering a broad spectrum of scientific and commercial disciplines.
Representatives of Quantumzyme expect to attend the conference and engage in informal networking meetings with industry participants. The Company will not be presenting, exhibiting, sponsoring, or formally participating in conference programming. This approach aligns with Quantumzyme's strategy to increase industry awareness and maintain dialogue with potential collaborators, technology partners, and other stakeholders.
“We view the BIO International Convention as an important opportunity to connect with peers across the biotechnology and biomanufacturing ecosystem,” said Naveen Kulkarni, Chief Executive Officer of Quantumzyme Corp. “Our attendance is focused on listening, learning, and engaging in informal discussions with industry participants as we continue to evaluate developments relevant to our technology and long-term objectives.”
Quantumzyme's attendance is limited to observation and networking activities only. There can be no assurance that discussions initiated during the conference will result in any agreements, transactions, or future business relationships. The company emphasizes that this participation is part of its ongoing efforts to stay informed about industry trends and to explore potential synergies with other organizations.
Additional information regarding the BIO International Convention is available at https://convention.bio.org. For more information and updates, please visit the Company's website at www.quantumzymecorp.com and its profile at www.otcmarkets.com/stock/QTZM.
Quantumzyme Corp. is a biotransformation company focused on advancing sustainable enzyme-based solutions for pharmaceutical manufacturing. Specializing in green chemistry, the company applies quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to develop biocatalysts designed to enhance efficiency, reduce waste, and support environmentally responsible production. By integrating computational modeling with laboratory validation, Quantumzyme aims to deliver scalable, cost-effective biocatalysis solutions that improve industrial sustainability.
The importance of this announcement lies in Quantumzyme's proactive engagement with the broader biotech community. As the pharmaceutical industry increasingly seeks sustainable manufacturing processes, Quantumzyme's enzyme-based solutions could play a crucial role in reducing environmental impact. Attendance at the BIO International Convention allows the company to stay abreast of the latest developments and forge connections that may accelerate the adoption of its green chemistry technologies.
